Close 2026-08-21 1267 scanned A

INDGN

Indegene Limited
HealthcareMid capRs 13,656 crRs 28.6 cr traded a day
Close on 2026-08-21
567.80
+0.19%
52-week range89% of the way up
423.50586.55
Market cap
13,656 cr
P/E (TTM)
34.1×
industry 44×
EPS (TTM)
16.67
Revenue YoY
+39.7%
Q1 FY27
Profit YoY
-0.2%
Net margin
10.9%
-4.4pt vs a year ago
Growth trend
+6.9pt
vs last quarter’s YoY
1 month
+16.2%
Below 52w high
3.3%
RSI (14)
63
Daily swing
3.1%
average true range
Volume
0.5×
vs 20-day average
Traded
Rs 29 cr
median day
Close200-day averageMaterial filing
450500550Aug 25Oct 25Dec 25Feb 26Apr 26Jun 26Aug 26
260 sessions · hover for the filing behind a move
1 week
+2.16%
1 month
+16.23%
3 months
+9.71%
6 months
+13.49%
1 year
+3.99%

The read

written from the numbers on this page
The evidence leans constructive6 supporting, 2 against, 0 worth knowing

Supporting

  • trading 12% above its 200-day average
  • sitting at 89% of its 52-week range, with little overhead supply from trapped buyers
  • up 4% over twelve months
  • 4 independent kinds of evidence agree today, which is uncommon
  • revenue grew 40% year on year in the quarter ending 2026-06-30
  • priced at 34× earnings against an industry median of 44× — 23% below its peers

Against

  • 1 of the scans it matches has historically underperformed the market
  • net margin has narrowed from 12.7% to 10.9% across four quarters

Worth knowing

  • nothing the data supports either way
What would change this read: a close below 505, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.

What is working, what is not

read from the filings, with the figure behind every line
Working1

Revenue +39.7% year on year, Rs 761 cr to Rs 1,063 cr.

+39.7%Rs 761 crRs 1,063 cr
Needs watching3

Profit grew slower than revenue, -0.2% against +39.7%.

-0.2%+39.7%

Net margin moved from 15.3% to 10.9%.

15.3%10.9%

Enterprise Commercial Solutions is 71% of revenue, so the business rests on one segment.

Enterprise Commercial Solutions71%
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.

How it has performed

price return over each window, measured against zero
+2.2%1W+16.2%1M+9.7%3M+13.5%6M+4.0%1Y

What the scans say today

6 of 47 matched on 2026-08-21
INDGN matches 6 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.

What this company does

segments and revenue mix, as the company reports them
INDGN reports 3 business segments. The largest is Enterprise Commercial Solutions at 71% of revenue in the quarter ending 2026-06-30.
SegmentRevenueSharevs a year ago
Enterprise Commercial Solutions750 cr70.6%
Enterprise Medical Solutions274 cr25.7%
Others39 cr3.7%
Segment names are the company’s own, taken verbatim from the reportable-segment disclosure in its quarterly XBRL filing. Nothing on this page describes the business in words we wrote.

Valuation against its own history

397 sessions since 2025-01-30
25×
median 31×
36×
now 34×
INDGN trades at 34× trailing earnings, above its median of 31× over this window — 10% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.

Recent filings

from the exchange, newest first
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Legal / regulatory filings were typically +0.99pt vs the market over the next 5 sessions (n=92) · Management filings were typically -0.01pt vs the market over the next 5 sessions (n=1,988)

The business

from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
6877207567618049421.0k1.1k13.4%15.6%7.9%10.9%Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.

Going for it

  • revenue grew 40% against the same quarter a year earlier
  • net margin widened from 7.9% to 10.9%
  • revenue rose in 4 of the last 4 quarters

Going against it

  • profit dropped 0% year on year
Quarter-by-quarter numbers, as filed
QuarterRevenueProfit before taxNet profitEPSNet margin
Q1 FY27
2026-06-30 · consolidated
1,0631531164.8410.9%
Q4 FY26
2026-03-31 · consolidated
1,003105803.327.9%
Q3 FY26
2025-12-31 · consolidated
9421351034.2910.9%
Q2 FY26
2025-09-30 · consolidated
8041331024.2612.7%
Q1 FY26
2025-06-30 · consolidated
7611521164.8615.3%
Q4 FY25
2025-03-31 · consolidated
7561491184.9115.6%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.

Where the price stands

the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+7.9%
Versus 200-day average+12.5%
Below 52-week high-3.2%
Above 52-week low+34.1%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)62.8
Higher closes in last 54 of 5
Six-month return+13.49%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.09%
Volume versus 20-day0.5x
Median daily turnoverRs 28.6 cr

Peers

Healthcare · 67 classified companies
INDGN trades at 34.1× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 23%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
CompanyMarket cap (Rs cr)P/E1 month1 yearTurnover (Rs cr)
SUNPHARMA456,44338.3−2.64%+21.54%363.8
DIVISLAB227,82077.9+17.69%+40.46%315.4
TORNTPHARM165,72780.1−3.33%+36.66%212.0
APOLLOHOSP125,00557.6−1.91%+13.16%257.5
CIPLA115,70034.5+2.81%−8.73%119.7
ZYDUSLIFE111,77625.5+0.56%+12.44%112.7
LUPIN100,67718.1−8.12%+16.52%259.0
MANKIND98,45947.6−6.78%−6.26%81.8
DRREDDY98,08730.8+0.72%−6.30%205.2
LAURUSLABS97,35389.3+14.90%+109.51%286.4
MAXHEALTH97,32466.8−7.77%−13.93%185.4
INDGN13,65634.1+16.23%+3.99%28.6
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet

Recent sessions

what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
SessionScansWhich
2026-08-181Bullish engulfing